Palatin Technologies Inc (PTN): Operating Income
-$8.67M
Year ended 2026-06-30
-$18.43M
Trailing 12 months to 2026-09-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | -$8.67M | n/m | 2026-09-28, From 2025-07-01 |
| 2025-06-30 | -$17.46M | n/m | 2026-09-28, From 2024-07-01 |
| 2024-06-30 | -$22.50M | n/m | 2025-09-23, From 2023-07-01 |
| 2023-06-30 | -$32.46M | n/m | 2024-09-30, From 2022-07-01 |
| 2022-06-30 | -$36.59M | n/m | 2023-09-28, From 2021-07-01 |
| 2021-06-30 | -$33.38M | n/m | 2022-09-22, From 2020-07-01 |
| 2020-06-30 | -$23.61M | n/m | 2021-09-28, From 2019-07-01 |
| 2019-06-30 | $35.74M | +37.9% | 2020-09-25, From 2018-07-01 |
| 2018-06-30 | $25.93M | 0.0% | 2019-09-12, From 2017-07-01 |
| 2017-06-30 | $25.93M | n/m | 2020-09-25, From 2016-07-01 |
| 2016-06-30 | -$49.25M | n/m | 2018-09-13, From 2015-07-01 |
| 2015-06-30 | -$17.29M | n/m | 2017-09-25, From 2014-07-01 |
| 2014-06-30 | -$15.79M | n/m | 2016-09-19, From 2013-07-01 |
| 2013-06-30 | -$15.59M | n/m | 2015-09-18, From 2012-07-01 |
| 2012-06-30 | -$18.79M | n/m | 2014-09-12, From 2011-07-01 |
| 2011-06-30 | -$13.65M | n/m | 2013-09-27, From 2010-07-01 |
| 2010-06-30 | -$3.01M | n/a | 2012-09-10, From 2009-07-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Palatin Technologies Inc (PTN) | 2026-06-30 | -$8.67M | n/m |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | -$125.70M | n/m |
| Evommune, Inc. (EVMN) | 2025-12-31 | -$81.07M | n/m |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | -$470.0K | n/m |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | -$84.42M | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $231.0K | n/m |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | -$38.16M | n/m |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | -$38.60M | n/m |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | -$104.57M | n/m |
Compare PTN, TNXP, EVMN, CVSI side by side · Screen every company in Pharmaceutical Preparations ↗